• Explore /
  • Poster
  • / Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT‑cx12/GOG 3057, trial in progress).

Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT‑cx12/GOG 3057, trial in progress).

Abstract Video & Slides Poster

Authors

Ignace Vergote

Ignace Vergote

Belgium and Luxembourg Gynaecological Oncology Group (BCOG), University of Leuven, Leuven Cancer Institute, Leuven, Belgium

Ignace Vergote , Bradley J. Monk , Robert L. Coleman , Leslie M. Randall , Keiichi Fujiwara , Christian Marth , Linn Lena Woelber , Els Van Nieuwenhuysen , David Cibula , Paula Calvert , Ingrid Boere , Antonio González-Martín , Elsa Kalbacher , Nicoletta Colombo , Domenica Lorusso , Susana N. Banerjee , Fernando C. Maluf , Ibrahima Soumaoro , Brian M. Slomovitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Clinical Trial Registration Number

NCT04697628

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS5596)

DOI

10.1200/JCO.2021.39.15_suppl.TPS5596

Abstract #

TPS5596

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Krishnansu Sujata Tewari

First Author: Luis Manso

First Author: Ignace Vergote

First Author: Isabelle Laure Ray-Coquard